AI platform using systems biology to design combination cancer therapies that overcome treatment resistance.
Serinus Biosciences develops an AI platform primed with systems biology knowledge to identify how cancer cells evolve treatment resistance and design combination therapies to overcome resistance escape routes. The platform aims to deliver safer, more effective combinations that reach patients faster. The company is founded by MIT PhDs and is based in New York. Limited public product detail is available on the website. Serinus Biosciences is a product of Serinus Biosciences.